<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Migraine with brainstem aura
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Migraine with brainstem aura
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Migraine with brainstem aura
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carrie Elizabeth Robertson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerry W Swanson, MD, MHPE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 11, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION AND DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Migraine with brainstem aura (MBA), previously called basilar-type migraine, is an uncommon form of migraine with aura characterized by brainstem symptoms such as dysarthria, vertigo, or ataxia, without evidence of motor weakness.
        </p>
        <p>
         This topic will review the clinical manifestations, diagnosis, and treatment of MBA. Other aspects of migraine are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">
          "Pathophysiology, clinical manifestations, and diagnosis of migraine in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6161.html" rel="external">
          "Pathophysiology, clinical features, and diagnosis of migraine in children"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">
          "Acute treatment of migraine in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3345.html" rel="external">
          "Preventive treatment of episodic migraine in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6168.html" rel="external">
          "Acute treatment of migraine in children"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/98355.html" rel="external">
          "Preventive treatment of migraine in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2779278699">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         MBA has previously been identified by other terms, reflecting an evolving understanding of the entity [
         <a href="#rid1">
          1
         </a>
         ]. These terms include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bickerstaff migraine
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basilar migraine
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basilar artery migraine
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basilar-type migraine
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vertebrobasilar migraine
        </p>
        <p>
        </p>
        <p>
         Originally described by Bickerstaff in 1961 as a clinical entity distinct from other forms of migraine [
         <a href="#rid2">
          2
         </a>
         ], earlier descriptions consistent with MBA were given by Aretaeus in ancient Greece and by Gowers in 1907 [
         <a href="#rid2">
          2-4
         </a>
         ]. It was previously considered a disorder of the basilar artery, but MBA is now the preferred term because there is no compelling evidence that the basilar artery is involved in the pathogenesis of the condition. Bickerstaff acknowledged that he had initially "rather loosely termed" this condition basilar artery migraine [
         <a href="#rid5">
          5
         </a>
         ]. In addition, some of the symptoms may localize to brain structures beyond the vascular territory of the basilar artery.
        </p>
        <p class="headingAnchor" id="H135982201">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         MBA is a subtype of migraine with aura, which is believed to occur when primary neuronal dysfunction leads to increased sensitivity to triggering stimuli. Onset of neuronal dysfunction in the hypothalamus or brainstem may lead to cortical spreading depression, a self-propagating wave of neuronal depolarization and glial activation that spreads across the cerebral cortex. Subsequent stimulation of the trigeminal nerve and neuronal release of vasoactive peptides including substance P, calcitonin gene-related peptide, and serotonin may trigger neurogenic inflammation and pain. (See
         <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">
          "Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Pathophysiology'
         </a>
         .)
        </p>
        <p>
         However, the pathophysiology of migraine is complex, and the pathogenesis of MBA may be multifactorial. Cortical spreading depression as the cause of altered local blood flow and metabolism in the brainstem has only been proven in animals [
         <a href="#rid6">
          6
         </a>
         ]. Alternative hypotheses suggest that MBA could originate in the cortex [
         <a href="#rid7">
          7
         </a>
         ]. Bickerstaff invoked the vascular hypothesis, the prevailing theory at the time, to explain the symptoms that were referable to either the brainstem or the bilateral occipital lobes [
         <a href="#rid2">
          2
         </a>
         ]. However, ictal spasm in the basilar or posterior cerebral arteries associated with MBA has only been reported in a few cases [
         <a href="#rid8">
          8-10
         </a>
         ]. Despite these few reports, it is unlikely that reversible ischemia is the source of the prolonged symptoms that occur with MBA.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Distinction from other forms of migraine
         </strong>
         – The difference between MBA and migraine with typical aura is that the location of the aura symptoms in MBA involves the brainstem or the bilateral occipital hemispheres, whereas in typical migraine the aura symptoms are mainly restricted to a unilateral hemisphere.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetics
         </strong>
         – Data are limited regarding the genetic basis of MBA. One study reported a mutation in the
         <em>
          ATP1A2
         </em>
         gene in three first-degree relatives with MBA [
         <a href="#rid11">
          11
         </a>
         ]. However, no causative mutation for MBA or genetic linkage was identified in a population-based study from Denmark [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In another study, a single patient with both MBA and episodic ataxia type 2 had a novel nonsense mutation in the
         <em>
          CACNA1A
         </em>
         gene, which has been frequently implicated in patients with familial hemiplegic migraine (FHM) [
         <a href="#rid13">
          13
         </a>
         ]. Some authors have suggested FHM may be a genetic form of MBA because nearly 75 percent of patients with hemiplegic migraine exhibit attacks that, if they did not include the additional hemiparesis, would otherwise fulfill diagnostic criteria for MBA [
         <a href="#rid1">
          1
         </a>
         ] (see
         <a class="local">
          'Diagnostic criteria'
         </a>
         below). These data suggest a shared pathogenetic mechanism between MBA and hemiplegic migraine and that they may be part of a phenotypic spectrum. (See
         <a class="medical medical_review" href="/z/d/html/14112.html" rel="external">
          "Hemiplegic migraine", section on 'Pathophysiology and genetics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         MBA is an uncommon form of migraine, but the actual incidence or prevalence is unknown, as various diagnostic criteria have been applied through the years without uniformity. In a population-based cohort study in Denmark, only 4 cases of MBA (1.37 percent) were found among 293 patients with migraine with aura; based on a reported prevalence of 4 percent for migraine with aura in the general population, the estimated prevalence of MBA may be 0.04 percent [
         <a href="#rid14">
          14
         </a>
         ]. Identifying MBA may also be challenging due to phenotypic overlap with other forms of migraine. In a study of 362 patients with migraine with aura (excluding auras featuring hemiplegia), MBA was identified in 38 patients (10 percent) [
         <a href="#rid12">
          12
         </a>
         ]. Among patients with MBA, preceding attacks of migraine with typical aura occurred in 36 (95 percent).
        </p>
        <p>
         Initially thought to occur only in adolescent females, MBA may affect patients at any age with a female to male ratio ranging from 1.3:1 to 3.8:1 [
         <a href="#rid12">
          12,15,16
         </a>
         ]. The age of onset is usually between 7 and 20 [
         <a href="#rid12">
          12,14,16
         </a>
         ]. MBA attacks can evolve to more typical common forms of migraine with age.
        </p>
        <p>
         As with other types of migraine, there is often a family history of migraine among individuals with MBA [
         <a href="#rid2">
          2,15,16
         </a>
         ]. In a series of 30 patients with MBA, a family history of migraine was present in 86 percent [
         <a href="#rid15">
          15
         </a>
         ]. A later age of onset of MBA tended to be associated with a more severe phenotype.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3127339802">
         <span class="h2">
          Aura
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical characteristics of MBA  (
         <a class="graphic graphic_table graphicRef73674" href="/z/d/graphic/73674.html" rel="external">
          table 1
         </a>
         ) were first described in Bickerstaff's 1961 report of 34 patients (26 females), who had attacks of aura lasting 2 to 45 minutes, most often with unilateral or bilateral hemianopic visual disturbance, vertigo, ataxia, dysarthria, bilateral tingling, or numbness [
         <a href="#rid2">
          2
         </a>
         ]. In other studies, the aura in MBA typically lasts from 5 to 60 minutes [
         <a href="#rid12">
          12,16
         </a>
         ]. However, the duration of the MBA aura ranges from several seconds up to 5 days in some patients [
         <a href="#rid12">
          12,17,18
         </a>
         ].
        </p>
        <p>
         Two or more aura symptoms always occur in attacks of MBA. The frequencies and range of brainstem symptoms were reported in a single center series [
         <a href="#rid12">
          12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vertigo – 61 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dysarthria – 53 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tinnitus – 45 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diplopia – 45 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bilateral visual symptoms – 40 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bilateral paresthesias – 24 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased level of consciousness – 24 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypacusis – 21 percent
        </p>
        <p>
        </p>
        <p>
         Impairment in or loss of consciousness has been more frequently reported in other studies, accompanying other aura symptoms in as many as 77 percent of patients with MBA [
         <a href="#rid16">
          16,19,20
         </a>
         ]. For such patients, confusion, stupor, or loss of consciousness may last 2 to 30 minutes. Prolonged impairment of consciousness (greater than two weeks) with marked generalized slow-wave delta activity has been reported in one patient with MBA [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Migraine triggers in MBA include emotional stress, menstruation, barometric pressure changes, head trauma, specific foods, medications, smoking, and exertion [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2730958583">
         <span class="h2">
          Headache
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with MBA develop a headache after the aura. In a Danish study of 38 patients with MBA, attacks of MBA were always associated with headache in 28 patients (74 percent), while attacks with or without headache occurred in 10 patients (26 percent) [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         In the initial description of MBA, headaches were described as throbbing in nature and occipital in location [
         <a href="#rid2">
          2
         </a>
         ]. However, the headache in MBA may localize to other areas of the head, similar to other forms of migraine with aura. The headache is typically severe and may be unilateral or bilateral [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H112263613">
         <span class="h2">
          Interictal symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurologic symptoms with MBA are most commonly transient and resolve after the attack. However, persisting symptoms have been reported in some patients. Specific brainstem localizing syndromes (eg, Wallenberg syndrome) and focal cranial nerve dysfunction have been rarely reported in MBA, perhaps because MBA is a manifestation of a maladaptive central nervous system [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
         Some patients with MBA have neuro-otologic abnormalities and may present for medical evaluation for dizziness or other vestibular symptoms. In one series of 50 patients with a history of MBA, most had minor vestibular abnormalities, and a few had severe peripheral injury thought to be a result of basilar migraine [
         <a href="#rid24">
          24
         </a>
         ]. Another series of 20 children with presumed MBA reported that 16 had abnormal bithermal caloric testing [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of MBA is suspected whenever a patient presents with episodic attacks of vertigo, dysarthria, diplopia, ataxia, confusion, or obtundation, particularly when in conjunction with more typical migraine auras consisting of visual, sensory, or aphasic symptoms.
        </p>
        <p>
         The diagnosis of MBA is made in patients who fulfill the diagnostic criteria, after alternative causes have been excluded. There are no diagnostic tests specific for MBA. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         below and
         <a class="local">
          'Testing to exclude alternative etiologies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnostic criteria for MBA from the International Classification of Headache Disorders, 3
         <sup>
          rd
         </sup>
         edition (ICHD-3) are as follows [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Attacks fulfilling criteria for migraine with aura  (
         <a class="graphic graphic_table graphicRef50876" href="/z/d/graphic/50876.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aura with both of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         At least two of the following fully reversible brainstem symptoms:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Dysarthria
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Vertigo
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Tinnitus
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hypacusis
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Diplopia
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Ataxia not attributable to sensory deficit
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Decreased level of consciousness (Glasgow Coma Scale  (
         <a class="graphic graphic_table graphicRef81854" href="/z/d/graphic/81854.html" rel="external">
          table 3
         </a>
         ) score ≤13)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No motor or retinal symptoms
        </p>
        <p>
        </p>
        <p>
         The presence of aura with motor symptoms excludes MBA and points to the diagnosis of hemiplegic migraine [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14112.html" rel="external">
          "Hemiplegic migraine", section on 'Diagnostic criteria'
         </a>
         .)
        </p>
        <p>
         The presence of an aura characterized by isolated vertigo points instead to a diagnosis of vestibular migraine. (See
         <a class="medical medical_review" href="/z/d/html/3356.html" rel="external">
          "Vestibular migraine", section on 'Diagnostic criteria'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3700337710">
         <span class="h2">
          Testing to exclude alternative etiologies
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest neuroimaging for all patients with first-ever MBA symptoms and for those with atypical presentations such as a prolonged aura, minor or absent head pain, abnormal interictal neurologic examination, or when symptoms are refractory to treatment, in agreement with guidelines from the American Headache Society [
         <a href="#rid26">
          26
         </a>
         ]. Other testing is used to exclude specific diagnostic entities in patients with suggestive symptoms.
        </p>
        <p>
         Repeat neuroimaging and other diagnostic testing are
         <strong>
          not
         </strong>
         required for patients with recurrent episodes that are typical for MBA.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuroimaging
         </strong>
         – We prefer magnetic resonance imaging (MRI) of the brain with contrast and magnetic resonance angiogram (MRA) of the intracranial and extracranial vessels to evaluate for posterior fossa parenchymal or vascular lesions. Examples include brainstem tumor, ischemic stroke or hemorrhage, vertebral or basilar artery thrombosis or dissection, cerebral aneurysms, or arteriovenous malformations. Computed tomography (CT) of the head and CT angiography (CTA) can be performed as an alternative to MRI and MRA or if MRI is contraindicated. Digital subtraction angiography may occasionally be warranted when noninvasive MRA or CTA imaging is nondiagnostic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Reversible MRI changes may occasionally be seen within the occipital cortex during acute attacks in some patients with MBA [
         <a href="#rid27">
          27
         </a>
         ]. These findings are felt to be due to vasogenic edema and resolve after the attack. However, no specific MRI findings are diagnostic of MBA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Electroencephalogram
         </strong>
         – An electroencephalogram (EEG) is performed in patients with impaired consciousness to exclude seizure activity. In addition, EEG may show transient (nonepileptiform) diffuse slowing associated with an MBA attack in patients with altered consciousness [
         <a href="#rid14">
          14
         </a>
         ]. In one study, slow waves on EEG found during the MBA attack subsequently resolved along with symptoms [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other testing
         </strong>
         – A 24-hour cardiac monitor may be used for patients with isolated brainstem symptoms such as dizziness or loss of consciousness to help identify episodic cardiac arrhythmias. Genetic testing is typically reserved for patients with a suggestive family history to evaluate for alternative syndromes such as hemiplegic migraine or episodic ataxia. Vestibular testing and audiometry are warranted for patients with prominent vestibular symptoms or associated hearing loss.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of MBA includes several conditions that also cause transient brainstem symptoms and signs with or without headache.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Common entities
         </strong>
         – The disorders that are most likely to resemble the symptom complex of MBA are transient ischemic attack (TIA) or ischemic stroke involving the brainstem and seizure  (
         <a class="graphic graphic_table graphicRef111740" href="/z/d/graphic/111740.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         TIA or ischemic stroke involving the brainstem, cerebellum, or posterior cerebral artery territory may be caused by thromboembolism, dissection, or atherosclerotic disease of the basilar artery or vertebral arteries. Features specific for cerebrovascular disease include restriction of symptoms to a specific vascular territory and diagnosis by neuroimaging. (See
         <a class="medical medical_review" href="/z/d/html/1102.html" rel="external">
          "Posterior circulation cerebrovascular syndromes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Focal seizures featuring brainstem symptoms may occur with or without convulsive activity. They may be preceded by a brief subjective sensory aura (eg, rising epigastric sensation). Other distinguishing features for seizure may be present including head deviation and dystonic limb posturing. EEG may be diagnostic. Ictal or postictal impairment of consciousness with a seizure is common. (See
         <a class="medical medical_review" href="/z/d/html/2231.html" rel="external">
          "Focal epilepsy: Causes and clinical features", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other conditions
         </strong>
         – Some primary headache disorders and other conditions characterized by clinical features also found in MBA may be distinguished by the specific pattern to symptoms, the presence of additional signs or symptoms, or by diagnostic testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Otologic or vestibular dysfunction
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Benign paroxysmal positional vertigo is characterized by transient episodes of movement-provoked, isolated vertigo. (See
         <a class="medical medical_review" href="/z/d/html/5098.html" rel="external">
          "Benign paroxysmal positional vertigo"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Ménière disease is an otologic disorder characterized by recurring episodes of vertigo, hearing loss, and tinnitus. Diagnostic evaluation typically includes audiometry, vestibular testing, and neuroimaging. (See
         <a class="medical medical_review" href="/z/d/html/6859.html" rel="external">
          "Meniere disease: Evaluation, diagnosis, and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Acute labyrinthitis, also called vestibular neuronitis, features vertigo, gait instability, and nystagmus, but headache and other brainstem features are uncommon. (See
         <a class="medical medical_review" href="/z/d/html/5102.html" rel="external">
          "Vestibular neuritis and labyrinthitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Impairment of consciousness
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Encephalopathy induced by a toxic-metabolic state or medication effect may be identified by clinical setting (eg, hospitalized patients), laboratory evaluation, or temporal relationship to medication dosing. (See
         <a class="medical medical_review" href="/z/d/html/4824.html" rel="external">
          "Diagnosis of delirium and confusional states"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Psychogenic attacks or behavioral spells that feature impairment of consciousness include psychogenic nonepileptic seizures and panic attacks. Other brainstem features are uncommon. (See
         <a class="medical medical_review" href="/z/d/html/2230.html" rel="external">
          "Nonepileptic paroxysmal disorders in adolescents and adults", section on 'Psychological disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ataxia
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Episodic ataxias are inherited conditions characterized by transient episodes of ataxia, nystagmus, and tremor. Episodic ataxias may be identified by genetic testing or a response to treatment with
         <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">
          acetazolamide
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/6234.html" rel="external">
          "Overview of the hereditary ataxias", section on 'Episodic ataxias'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Headache
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Familial or sporadic hemiplegic migraine requires the presence of motor weakness as a component of the aura, in contradistinction from MBA. (See
         <a class="medical medical_review" href="/z/d/html/14112.html" rel="external">
          "Hemiplegic migraine"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Vestibular migraine is a form of migraine with an aura consisting of isolated vestibular symptoms, distinct from MBA that features aura consisting of at least two brainstem symptoms. (See
         <a class="medical medical_review" href="/z/d/html/3356.html" rel="external">
          "Vestibular migraine"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy is a rare syndrome that features migraine, ischemic stroke, and chronic cognitive impairment. (See
         <a class="medical medical_review" href="/z/d/html/1091.html" rel="external">
          "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Subarachnoid hemorrhage from a ruptured cerebral aneurysm may present with a thunderclap headache and other symptoms related to the site of bleeding. Diagnosis is by neuroimaging or lumbar puncture. (See
         <a class="medical medical_review" href="/z/d/html/1130.html" rel="external">
          "Aneurysmal subarachnoid hemorrhage: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Tumors of the posterior fossa may present with progressive headaches due to compression of brain structures or hydrocephalus as well as other neurologic symptoms related to the location of the tumor. Diagnosis is typically by neuroimaging. (See
         <a class="medical medical_review" href="/z/d/html/5180.html" rel="external">
          "Overview of the clinical features and diagnosis of brain tumors in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5217.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of brain metastases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Chiari I malformation most commonly presents with headache but may also cause other neurologic symptoms including ataxia, cranial neuropathies, and myelopathy. Diagnosis is by identification of cerebellar and brainstem descent on neuroimaging. (See
         <a class="medical medical_review" href="/z/d/html/13507.html" rel="external">
          "Chiari malformations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Cerebral venous thrombosis (CVT) most frequently presents with new headache, with or without neurologic signs. Some patients present with focal symptoms or encephalopathy due to elevated intracranial pressure or stroke. Neuroimaging, including with CT or MR venography, is used to identify CVT. (See
         <a class="medical medical_review" href="/z/d/html/1103.html" rel="external">
          "Cerebral venous thrombosis: Etiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to treatment for patients with MBA includes acute therapies to manage active symptoms and preventive therapies for patients with frequent, prolonged, or debilitating attacks. Acute and preventive medication options for patients with MBA are based largely on those used for patients with migraine with aura because available data on treatment of patients with MBA are limited. However, medications that may theoretically cause or exacerbate cerebral ischemia are
         <strong>
          avoided
         </strong>
         in patients with MBA. (See
         <a class="local">
          'Medications to avoid'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H135982410">
         <span class="h2">
          Acute therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest an antiemetic medication or a nonsteroidal anti-inflammatory drug (NSAID) for initial acute symptomatic treatment of patients with MBA. Oral NSAIDs are widely available and inexpensive and may be preferred for patients with milder symptoms. Intravenous (IV) or intramuscular (IM) NSAIDs or antiemetic medications may be preferred for patients with moderate to severe headaches or those that are associated with prominent nausea and vomiting.
        </p>
        <p>
         For patients with mild to moderate MBA symptoms, options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          Ibuprofen
         </a>
         400 to 600 mg orally once
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">
          Naproxen
         </a>
         sodium 275 to 750 mg orally once
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">
          Diclofenac
         </a>
         50 to 100 mg orally once
        </p>
        <p>
        </p>
        <p>
         For patients with moderate to severe MBA symptoms or significant nausea/vomiting, options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">
          Ketorolac
         </a>
         30 mg IV or 60 mg IM once (lower doses may be warranted for patients age ≥65 years, &lt;50 kg body weight, or those with kidney impairment)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">
          Prochlorperazine
         </a>
         10 mg IV, IM, or orally once
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">
          Metoclopramide
         </a>
         10 mg IV or orally once
        </p>
        <p>
        </p>
        <p>
         NSAIDs and antiemetic agents may also be used as combination therapy.
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          Diphenhydramine
         </a>
         (25 to 50 mg orally) may be given along with antiemetic medications to prevent akathisia and acute dystonic reactions.
        </p>
        <p>
         Alternative options for acute symptomatic treatment of MBA include calcitonin gene-related peptide antagonists (eg,
         <a class="drug drug_general" data-topicid="127256" href="/z/d/drug information/127256.html" rel="external">
          rimegepant
         </a>
         and
         <a class="drug drug_general" data-topicid="126412" href="/z/d/drug information/126412.html" rel="external">
          ubrogepant
         </a>
         ) and the serotonin 1F receptor agonist
         <a class="drug drug_general" data-topicid="122892" href="/z/d/drug information/122892.html" rel="external">
          lasmiditan
         </a>
         , based on data for and experience with episodic migraine [
         <a href="#rid20">
          20
         </a>
         ]. However, efficacy and safety in patients with MBA has not been studied. Greater occipital nerve blockade using 3 cc of 0.25 percent
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         combined with 40 mg
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         aborted an MBA attack in a single case report [
         <a href="#rid29">
          29
         </a>
         ]. One case of MBA was treated with 0.8 mg of
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Acute migraine treatments are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">
          "Acute treatment of migraine in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Preventive therapy
         </span>
        </p>
        <p class="headingAnchor" id="H508108111">
         <span class="h3">
          First-line options
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with MBA who desire preventive therapy because the attacks are frequent, prolonged, or debilitating, we suggest initial treatment with either sustained-release
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         or
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         . For adult patients with MBA who fail to benefit with verapamil or topiramate or those who have persistent aura symptoms that predominate over headache, we suggest treatment with
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          Verapamil
         </a>
         (sustained-release formulation) is started at 120 mg once daily. The dose can be increased by 120 mg every one to two weeks, based on response and tolerability, up to 360 mg daily given in two to three divided doses. However, we suggest using no more than 120 mg daily for small or older adults and those with hypotension or cardiac conditions. An electrocardiogram should be performed prior to starting verapamil and if cardiac symptoms develop. Adverse effects of verapamil are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3832.html" rel="external">
          "Major side effects and safety of calcium channel blockers"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          Topiramate
         </a>
         is started at 25 mg daily and increased by 25 mg weekly to 100 mg daily as necessary and tolerated or to 200 mg daily in divided doses for patients with a partial response to lower doses. We suggest not using topiramate during pregnancy, due to fetal adverse risks. Topiramate dosing and adverse effects are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Topiramate'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          Lamotrigine
         </a>
         is started at 25 mg daily with slow titration increasing by 25 mg every one to two weeks up to 100 mg per day, based on clinical response and tolerability. Systemic symptoms including rashes and angioedema may occur if dose escalation is too rapid. Lamotrigine should be avoided in patients with cardiac conduction disorders. Lamotrigine dosing and adverse effects are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Lamotrigine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          Verapamil
         </a>
         is used for preventive therapy of MBA largely due to its successful use in patients with hemiplegic migraine [
         <a href="#rid30">
          30
         </a>
         ]. A prospective study of 14 children with MBA reported that prophylaxis with
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         at both 25 mg daily and 100 mg daily was associated with a significant reduction in overall migraine and MBA frequency [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         In a case series of 47 patients who had migraine with aura, including six who had MBA,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         was reported as beneficial in approximately two-thirds [
         <a href="#rid32">
          32
         </a>
         ]. However, an earlier randomized controlled trial did not demonstrate benefit of lamotrigine for migraine prophylaxis in patients with and without aura [
         <a href="#rid33">
          33
         </a>
         ]. Of concern, a benign rash may develop in up to 10 percent of patients during the initial one to two months of lamotrigine therapy and necessitates discontinuation of the drug; the risk of developing a life-threatening rash such as Stevens-Johnson syndrome is approximately 1 in 1000 adults. This risk is higher in children, leading to the recommendation that the drug not be used in patients under the age of 16 years.
        </p>
        <p class="headingAnchor" id="H1105466834">
         <span class="h3">
          Alternative options
         </span>
         <span class="headingEndMark">
          —
         </span>
         Botulinum toxin injections may also be an option for patients with MBA unresponsive to oral agents. In a case series of 11 patients with hemiplegic migraine,
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         injections were associated with a reduced frequency and duration of aura in nine patients, including one patient who had symptoms that resembled MBA, with prominent ataxia/dysarthria and presyncope/syncope [
         <a href="#rid34">
          34
         </a>
         ]. Of the 11 patients in this series, 10 met criteria for chronic migraine. Dosing for patients with MBA is based on injection protocols used for patients with chronic migraine. (See
         <a class="medical medical_review" href="/z/d/html/3337.html" rel="external">
          "Chronic migraine", section on 'Botulinum toxin'
         </a>
         .)
        </p>
        <p>
         There is meager evidence to support the use of other preventive medications for MBA.
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          Phenytoin
         </a>
         and
         <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">
          primidone
         </a>
         were associated with improvement of MBA in a few patients [
         <a href="#rid35">
          35
         </a>
         ]. Since MBA is a subset of migraine with aura, preventive medications for migraine such as
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         , or calcitonin gene-related peptide antagonists may be beneficial if first-line options are ineffective or intolerable. (See
         <a class="medical medical_review" href="/z/d/html/3345.html" rel="external">
          "Preventive treatment of episodic migraine in adults"
         </a>
         .)
        </p>
        <p>
         The use of
         <a class="drug drug_general" data-topicid="8869" href="/z/d/drug information/8869.html" rel="external">
          flunarizine
         </a>
         for MBA is also based upon its apparent benefit for hemiplegic migraine; flunarizine is not available in the United States. (See
         <a class="medical medical_review" href="/z/d/html/14112.html" rel="external">
          "Hemiplegic migraine", section on 'Abortive and preventive medications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2944798193">
         <span class="h2">
          Medications to avoid
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some medications used for migraine treatment may lead to cerebral ischemia, based on anecdotal evidence and theoretical concerns [
         <a href="#rid36">
          36-38
         </a>
         ]. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Triptans
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9416" href="/z/d/drug information/9416.html" rel="external">
          Ergotamine
         </a>
         derivatives
        </p>
        <p>
        </p>
        <p>
         We typically
         <strong>
          avoid
         </strong>
         these medications for patients with MBA and frequent or long-lasting auras or auras associated with prominent ataxia or a decreased level of consciousness but may consider their use for selected patients with MBA and auras associated with vertigo, tinnitus, hypacusis, or diplopia.
        </p>
        <p>
         Triptans and
         <a class="drug drug_general" data-topicid="9416" href="/z/d/drug information/9416.html" rel="external">
          ergotamine
         </a>
         derivatives are generally felt to be contraindicated in MBA because of the potential for cerebral vasoconstriction. Some experts have argued that this theoretical risk is based primarily on the relatively outdated vascular theory of migraine, and the contraindication should be reconsidered [
         <a href="#rid39">
          39-42
         </a>
         ]. Small retrospective, observational reports of patients with MBA, hemiplegic migraine, or prolonged aura have shown no serious adverse effects with the use of triptans [
         <a href="#rid40">
          40,43
         </a>
         ] or
         <a class="drug drug_general" data-topicid="9363" href="/z/d/drug information/9363.html" rel="external">
          dihydroergotamine
         </a>
         [
         <a href="#rid43">
          43,44
         </a>
         ]. However, historical concerns of worsening vasoconstriction have kept patients with MBA out of larger triptan and dihydroergotamine trials.
        </p>
        <p>
         Some headache specialists also avoid beta blockers as preventive therapy for patients who have MBA, hemiplegic migraine, or migraine with prolonged aura [
         <a href="#rid45">
          45
         </a>
         ]. The concern is that beta blockers may potentially limit compensatory vasodilatory capacitance of cerebral vessels. Similar to hemiplegic migraine, anecdotal evidence suggests that beta blockers may lead to ischemia in patients with MBA [
         <a href="#rid45">
          45,46
         </a>
         ]. However, multiple case reports have shown an excellent response to treatment with beta blockers for patients with MBA [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H154295598">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are limited data regarding the prognosis of MBA. However, like other forms of migraine, individual attacks of MBA are self-limited and fully reversible in nearly all instances, despite the paroxysmal and alarming nature of the symptoms [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Furthermore, the overall prevalence of migraine decreases with age; MBA attacks may remit or evolve to more typical forms of migraine as patients get older. As an example, a retrospective analysis of subjects with onset of migraine with aura in childhood or adolescence identified 13 with MBA [
         <a href="#rid48">
          48
         </a>
         ]. Over a mean follow-up of 11 years, complete remission of headache attacks was noted in five patients, five patients had changed to a different type of headache (eg, migraine without aura or tension-type headache), and MBA persisted in three.
        </p>
        <p>
         Migrainous infarction may be a rare complication of migraine with aura, though data are limited in MBA. In addition, there is evidence that migraine with aura is associated with a small absolute increase in the overall risk of ischemic stroke. Cerebrovascular complications of migraine are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3344.html" rel="external">
          "Migraine-associated stroke: risk factors, diagnosis, and prevention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1973790903">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110285.html" rel="external">
          "Society guideline links: Migraine and other primary headache disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/719.html" rel="external">
          "Patient education: Headache causes and diagnosis in adults (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/720.html" rel="external">
          "Patient education: Headache treatment in adults (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and terminology
         </strong>
         – Migraine with brainstem aura (MBA), previously called basilar-type migraine, is an uncommon form of migraine with aura with brainstem signs and symptoms but without weakness. (See
         <a class="local">
          'Introduction and definition'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features and diagnosis
         </strong>
         – The diagnosis of MBA includes headache attacks consistent with migraine with aura  (
         <a class="graphic graphic_table graphicRef50876" href="/z/d/graphic/50876.html" rel="external">
          table 2
         </a>
         ) and aura with two or more brainstem-related symptoms  (
         <a class="graphic graphic_table graphicRef73674" href="/z/d/graphic/73674.html" rel="external">
          table 1
         </a>
         ) but excluding motor weakness. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Common aura symptoms in MBA include vertigo, dysarthria, tinnitus, visual disturbance, and impairment in consciousness. The aura generally develops over ≥5 minutes, may last up to 60 minutes or longer, and is typically followed by headache. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation for alternative etiologies
         </strong>
         – We suggest neuroimaging for patients with first-ever MBA symptoms and for those with atypical presentations such as a prolonged aura, minor or absent head pain, abnormal interictal neurologic examination, or when symptoms are refractory to treatment. Repeat neuroimaging and other diagnostic testing is
         <strong>
          not
         </strong>
         required for patients with recurrent features typical for MBA. (See
         <a class="local">
          'Testing to exclude alternative etiologies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of MBA includes several conditions that also cause brainstem symptoms and signs including ischemic stroke, seizure, and other conditions that may also present with brainstem signs (ataxia, vestibular dysfunction, impairment in consciousness) or headache. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acute treatment
         </strong>
         – We suggest an antiemetic medication or a nonsteroidal anti-inflammatory drug for acute symptomatic treatment of patients with MBA based on efficacy and tolerability for patients with other forms of migraine (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Alternative options include calcitonin gene-related peptide antagonists (eg,
         <a class="drug drug_general" data-topicid="127256" href="/z/d/drug information/127256.html" rel="external">
          rimegepant
         </a>
         and
         <a class="drug drug_general" data-topicid="126412" href="/z/d/drug information/126412.html" rel="external">
          ubrogepant
         </a>
         ) and
         <a class="drug drug_general" data-topicid="122892" href="/z/d/drug information/122892.html" rel="external">
          lasmiditan
         </a>
         . (See
         <a class="local">
          'Acute therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial preventive medications
         </strong>
         – For patients with MBA who desire preventive therapy because the attacks are frequent, prolonged, or debilitating, we suggest initial treatment with either sustained-release
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         or
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Preventive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          Verapamil
         </a>
         (sustained-release formulation) is started at 120 mg once daily and can be increased by 120 mg based on response and tolerability every one to two weeks up to 360 mg daily given in two to three divided doses. However, we suggest using no more than 120 mg daily for small or older adults and those with hypotension or cardiac conditions.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          Topiramate
         </a>
         is started at 25 mg daily and increased by 25 mg weekly to 100 mg daily as necessary and tolerated or to 200 mg daily in divided doses for patients with a partial response to lower doses who are tolerating the medicine well.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          Lamotrigine
         </a>
         is an alternative treatment for adult patients who do not benefit from or tolerate treatment with
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         or
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         and for those who have persistent aura symptoms that predominate over headache. Lamotrigine is started at 25 mg daily with slow titration increasing by 25 mg every one to two weeks up to 100 mg per day, based on clinical response and tolerability.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alternative preventive options
         </strong>
         – Other preventive medications used for migraine may be beneficial for patients with MBA who do not respond to initial preventive therapy. Options include
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         , or calcitonin gene-related peptide antagonists. (See
         <a class="local">
          'Alternative options'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Medications to avoid
         </strong>
         – We typically
         <strong>
          avoid
         </strong>
         triptans and
         <a class="drug drug_general" data-topicid="9416" href="/z/d/drug information/9416.html" rel="external">
          ergotamine
         </a>
         derivatives for patients with MBA and frequent or long-lasting auras or auras associated with prominent ataxia or a decreased level of consciousness due to theoretical concerns and anecdotal evidence that these medications may lead to cerebral ischemia. (See
         <a class="local">
          'Medications to avoid'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H204236461">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges David F Black, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bickerstaff ER. Basilar artery migraine. Lancet 1961; 1:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pearce JM. Historical aspects of migraine. J Neurol Neurosurg Psychiatry 1986; 49:1097.
          </a>
         </li>
         <li class="breakAll">
          Gowers WR. The Borderland of Epilepsy: Faints, vagal attacks, vertigo, sleep, symptoms, and their treatment, Churchill, London 1907.
         </li>
         <li>
          <a class="nounderline abstract_t">
           BICKERSTAFF ER. The basilar artery and the migraine-epilepsy syndrome. Proc R Soc Med 1962; 55:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mraovitch S, Calando Y, Goadsby PJ, Seylaz J. Subcortical cerebral blood flow and metabolic changes elicited by cortical spreading depression in rat. Cephalalgia 1992; 12:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demarquay G, Ducros A, Montavont A, Mauguiere F. Migraine with brainstem aura: Why not a cortical origin? Cephalalgia 2018; 38:1687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen TS, de Fine Olivarius B, Kraft M, Hansen HJ. Familial hemiplegic migraine--a reappraisal and a long-term follow-up study. Cephalalgia 1981; 1:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laurent B, Michel D, Antoine JC, Montagnon D. [Basilar migraine with alexia but not agraphia: arterial spasm on arteriography and the effect of naloxone]. Rev Neurol (Paris) 1984; 140:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           La Spina I, Vignati A, Porazzi D. Basilar artery migraine: transcranial Doppler EEG and SPECT from the aura phase to the end. Headache 1997; 37:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambrosini A, D'Onofrio M, Grieco GS, et al. Familial basilar migraine associated with a new mutation in the ATP1A2 gene. Neurology 2005; 65:1826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirchmann M, Thomsen LL, Olesen J. Basilar-type migraine: clinical, epidemiologic, and genetic features. Neurology 2006; 66:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robbins MS, Lipton RB, Laureta EC, Grosberg BM. CACNA1A nonsense mutation is associated with basilar-type migraine and episodic ataxia type 2. Headache 2009; 49:1042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamani N, Chalmer MA, Olesen J. Migraine with brainstem aura: defining the core syndrome. Brain 2019; 142:3868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lapkin ML, Golden GS. Basilar artery migraine. A review of 30 cases. Am J Dis Child 1978; 132:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sturzenegger MH, Meienberg O. Basilar artery migraine: a follow-up study of 82 cases. Headache 1985; 25:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi FH, Gonzalez E, Rossi EM, Tsakadze N. Exploding Head Syndrome as Aura of Migraine with Brainstem Aura: A Case Report. J Oral Facial Pain Headache 2018; 32:e34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee CH, Lance JW. Migraine stupor. Headache 1977; 17:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BICKERSTAFF ER. Impairment of consciousness in migraine. Lancet 1961; 2:1057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu SY, Li HJ, Huang J, et al. Migraine with Brainstem Aura Accompanied by Disorders of Consciousness. J Pain Res 2021; 14:1119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muellbacher W, Mamoli B. Prolonged impaired consciousness in basilar artery migraine. Headache 1994; 34:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sulkava R, Kovanen J. Locked-in syndrome with rapid recovery: a manifestation of basilar artery migraine? Headache 1983; 23:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon GD, Spaccavento LJ. Lateral medullary syndrome after basilar migraine. Headache 1982; 22:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsson JE. Neurotologic findings in basilar migraine. Laryngoscope 1991; 101:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eviatar L. Vestibular testing in basilar artery migraine. Ann Neurol 1981; 9:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans RW, Burch RC, Frishberg BM, et al. Neuroimaging for Migraine: The American Headache Society Systematic Review and Evidence-Based Guideline. Headache 2020; 60:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maytal J, Libman RB, Lustrin ES. Basilar artery migraine and reversible imaging abnormalities. AJNR Am J Neuroradiol 1998; 19:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park JJ, Kim SJ, Kim HY, et al. Migraine with Aura as a Stroke Mimic. Can J Neurol Sci 2020; 47:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baron EP, Tepper SJ, Mays M, Cherian N. Acute treatment of basilar-type migraine with greater occipital nerve blockade. Headache 2010; 50:1057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans RW, Linder SL. Management of basilar migraine. Headache 2002; 42:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis D, Paradiso E. A double-blind, dose comparison study of topiramate for prophylaxis of basilar-type migraine in children: a pilot study. Headache 2007; 47:1409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pascual J, Caminero AB, Mateos V, et al. Preventing disturbing migraine aura with lamotrigine: an open study. Headache 2004; 44:1024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997; 17:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen TY, Garza I, Dodick DW, Robertson CE. The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients. Headache 2018; 58:973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swanson JW, Vick NA. Basilar artery migraine 12 patients, with an attack recorded electroencephalographically. Neurology 1978; 28:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jamieson DG. The safety of triptans in the treatment of patients with migraine. Am J Med 2002; 112:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992; 117:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russell MB, Ducros A. Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurol 2011; 10:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaniecki RG. Basilar-type migraine. Curr Pain Headache Rep 2009; 13:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klapper J, Mathew N, Nett R. Triptans in the treatment of basilar migraine and migraine with prolonged aura. Headache 2001; 41:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vgontzas A, Burch R. Episodic Migraine With and Without Aura: Key Differences and Implications for Pathophysiology, Management, and Assessing Risks. Curr Pain Headache Rep 2018; 22:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathew PG, Klein BC. Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk. Headache 2019; 59:1421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathew PG, Krel R, Buddhdev B, et al. A retrospective analysis of triptan and dhe use for basilar and hemiplegic migraine. Headache 2016; 56:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whyte CA, Stillman MJ, Tepper SJ. Dihydroergotamine and its use in migraine with posterior fossa symptoms. Headache 2010; 50:1419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans RW, Lipton RB. Topics in migraine management: a survey of headache specialists highlights some controversies. Neurol Clin 2001; 19:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bardwell A, Trott JA. Stroke in migraine as a consequence of propranolol. Headache 1987; 27:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bahemuka M. Basilar artery migraine in a child: excellent response to propranolol. East Afr Med J 1981; 58:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Termine C, Ferri M, Livetti G, et al. Migraine with aura with onset in childhood and adolescence: long-term natural history and prognostic factors. Cephalalgia 2010; 30:674.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3352 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29368949" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Basilar artery migraine
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3537212" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Historical aspects of migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3537212" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Historical aspects of migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13868978" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The basilar artery and the migraine-epilepsy syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1623507" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Subcortical cerebral blood flow and metabolic changes elicited by cortical spreading depression in rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29073774" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Migraine with brainstem aura: Why not a cortical origin?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15645832" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Familial hemiplegic migraine--a reappraisal and a long-term follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6505494" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : [Basilar migraine with alexia but not agraphia: arterial spasm on arteriography and the effect of naloxone].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9046723" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Basilar artery migraine: transcranial Doppler EEG and SPECT from the aura phase to the end.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16344534" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Familial basilar migraine associated with a new mutation in the ATP1A2 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16567706" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Basilar-type migraine: clinical, epidemiologic, and genetic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19486177" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : CACNA1A nonsense mutation is associated with basilar-type migraine and episodic ataxia type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31789370" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Migraine with brainstem aura: defining the core syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/629244" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Basilar artery migraine. A review of 30 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4086291" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Basilar artery migraine: a follow-up study of 82 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29694468" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Exploding Head Syndrome as Aura of Migraine with Brainstem Aura: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/845025" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Migraine stupor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13868977" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Impairment of consciousness in migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33907459" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Migraine with Brainstem Aura Accompanied by Disorders of Consciousness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8026947" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Prolonged impaired consciousness in basilar artery migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6629768" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Locked-in syndrome with rapid recovery: a manifestation of basilar artery migraine?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7107245" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Lateral medullary syndrome after basilar migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1984561" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Neurotologic findings in basilar migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7235628" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Vestibular testing in basilar artery migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31891197" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Neuroimaging for Migraine: The American Headache Society Systematic Review and Evidence-Based Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9672022" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Basilar artery migraine and reversible imaging abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31657289" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Migraine with Aura as a Stroke Mimic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20487035" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Acute treatment of basilar-type migraine with greater occipital nerve blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12047342" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Management of basilar migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18052950" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A double-blind, dose comparison study of topiramate for prophylaxis of basilar-type migraine in children: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15546267" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Preventing disturbing migraine aura with lamotrigine: an open study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9137848" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Lamotrigine versus placebo in the prophylaxis of migraine with and without aura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29762872" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/567295" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Basilar artery migraine 12 patients, with an attack recorded electroencephalographically.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11835952" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The safety of triptans in the treatment of patients with migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1596047" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21458376" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19457282" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Basilar-type migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11903526" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Triptans in the treatment of basilar migraine and migraine with prolonged aura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30291554" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Episodic Migraine With and Without Aura: Key Differences and Implications for Pathophysiology, Management, and Assessing Risks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31318457" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27062528" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A retrospective analysis of triptan and dhe use for basilar and hemiplegic migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20533960" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Dihydroergotamine and its use in migraine with posterior fossa symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11471758" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Topics in migraine management: a survey of headache specialists highlights some controversies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3654198" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Stroke in migraine as a consequence of propranolol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7215278" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Basilar artery migraine in a child: excellent response to propranolol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20511205" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Migraine with aura with onset in childhood and adolescence: long-term natural history and prognostic factors.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
